Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board ...
UnitedHealth shares a quarterly report for the first time since the death of insurance unit leader Brian Thompson. A look at ...
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...